AARTIDRUGS · NSE
Aarti Drugs Limited
₹484.5
-2.89% (-₹14.4)
Prev. close
₹498.9
Volume
2,92,093
Delivery %
36.7%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Aarti Drugs, recommending a buy at ₹480.60 with a target of ₹530 and a stop loss at ₹455, based on technical …” | Sumeet BagadiaChoice Equity Broking | Aarti Drugs Ltd | PENDING |
Fundamentals
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzenesulphonyl chloride, benzenesulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rashesh Chandrakant Gogri
Headquarters
Mumbai
Employees
1,355
Website
aartidrugs.co.inExchange
View on NSE ↗Key stats
Market cap
₹4,174.23 Cr
P/E ratio (TTM)
22.4
Dividend yield
0.43%
EPS (TTM)
₹20.46
Beta (1Y · daily vs NIFTY 50)
0.76
Beta (5Y · monthly vs NIFTY 50)
0.95
Shares float
3.54 Cr
EPS · quarter ended Jun 2026
₹5.49
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,154.78 Cr | ₹2,488.65 Cr | ₹2,716.05 Cr | ₹2,528.58 Cr | ₹2,387.03 Cr | ₹2,565.31 Cr | |
EBITDA | ₹441.85 Cr | ₹340.76 Cr | ₹307.79 Cr | ₹320.50 Cr | ₹303.42 Cr | ₹311.58 Cr |
| ₹280.00 Cr | ₹205.00 Cr | ₹166.31 Cr | ₹171.42 Cr | ₹168.16 Cr | ₹194.92 Cr | |
Diluted EPS | ₹30.09 | ₹22.12 | ₹17.97 | ₹18.56 | ₹18.35 | ₹21.36 |
09 · Balance Sheet — as filed
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹1,111.64 Cr | ₹1,236.32 Cr | ₹1,347.49 Cr | |
Inventories | ₹485.89 Cr | ₹472.93 Cr | ₹490.78 Cr |
(0) Trade Receivable | ₹704.55 Cr | ₹751.18 Cr | ₹829.87 Cr |
(ii) Cash and Cash Equivalents | ₹6.74 Cr | ₹4.58 Cr | ₹7.27 Cr |
(iii) Bank Balances Other than (ii) above | ₹2.69 Cr | ₹2.98 Cr | ₹1.54 Cr |
(iv) Loan | ₹23.66 L | ₹75.77 L | ₹70.30 L |
(v) Other Financial Assets | ₹11.34 Cr | ₹15.05 Cr | ₹15.47 Cr |
| ₹1,320.72 Cr | ₹1,338.36 Cr | ₹1,467.77 Cr | |
TOTAL ASSETS | ₹2,432.36 Cr | ₹2,574.68 Cr | ₹2,815.26 Cr |
| ₹1,281.95 Cr | ₹1,369.34 Cr | ₹1,549.23 Cr | |
| ₹1,281.55 Cr | ₹1,369.00 Cr | ₹1,548.86 Cr | |
Non- Controlling Interests | ₹40.58 L | ₹34.43 L | ₹36.46 L |
(i) Borrowings | ₹275.33 Cr | ₹284.00 Cr | ₹256.87 Cr |
(ii) Lease Liabilities | ₹91.40 L | ₹1.65 Cr | ₹85.99 L |
(ii) Other financial liabilities | ₹16.99 L | ₹16.01 L | ₹23.16 L |
| ₹354.86 Cr | ₹368.37 Cr | ₹343.78 Cr | |
(i) Borrowings | ₹287.09 Cr | ₹328.24 Cr | ₹317.96 Cr |
(ii) Lease Liabilities | ₹94.96 L | ₹1.18 Cr | ₹94.65 L |
Dues of micro enterprises and small enterprises | ₹13.98 Cr | — | — |
Dues of creditors other micro enterprises and small enterprises | ₹411.51 Cr | — | — |
(a) Total outstanding dues of micro and small enterprises | — | ₹11.80 Cr | ₹24.09 Cr |
(b) Total outstanding dues of other than micro and small enterprises | — | ₹404.34 Cr | ₹453.79 Cr |
(iv) Other Financial Liabilities | ₹26.33 Cr | ₹20.23 Cr | ₹22.80 Cr |
| — | ₹836.97 Cr | ₹922.26 Cr | |
TOTAL EQUITY AND LIABILITIES | ₹2,432.36 Cr | ₹2,574.68 Cr | ₹2,815.26 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2.04 Cr | ₹12.80 Cr | ₹-14.11 Cr | ₹-76.07 L | ₹-2.17 Cr | ₹2.69 Cr | |
| ₹154.95 Cr | ₹70.41 Cr | ₹133.32 Cr | ₹358.92 Cr | ₹244.58 Cr | ₹253.54 Cr | |
| ₹-71.78 Cr | ₹-149.64 Cr | ₹-163.97 Cr | ₹-223.65 Cr | ₹-164.63 Cr | ₹-173.41 Cr | |
| ₹-81.13 Cr | ₹92.03 Cr | ₹16.54 Cr | ₹-136.03 Cr | ₹-82.12 Cr | ₹-77.44 Cr | |
Opening Cash and Cash Equivalents | ₹6.77 Cr | ₹8.81 Cr | ₹21.61 Cr | ₹7.50 Cr | ₹6.74 Cr | ₹4.58 Cr |
Closing Cash and Cash Equivalents | ₹8.81 Cr | ₹21.61 Cr | ₹7.50 Cr | ₹6.74 Cr | ₹4.58 Cr | ₹7.27 Cr |
| ₹8.81 Cr | ₹21.61 Cr | ₹7.50 Cr | ₹6.74 Cr | — | — | |
Balance with Banks | ₹6.96 Cr | ₹20.84 Cr | ₹6.34 Cr | ₹4.43 Cr | — | — |
Cash in Hand | ₹29.95 L | ₹24.33 L | ₹28.24 L | ₹26.17 L | — | — |
Cheques in Hand | ₹1.55 Cr | ₹52.65 L | ₹88.01 L | ₹2.05 Cr | — | — |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.12% | 59.99% | 59.83% | 59.98% | 59.77% | 59.66% | 59.58% | 58.70% | 58.56% | 57.47% | 57.13% | 55.67% | 55.64% | 55.38% | 55.48% | 55.22% | 54.72% | 55.03% | 54.43% |
| Public | 39.88% | 40.01% | 40.17% | 40.02% | 40.23% | 40.34% | 40.42% | 41.30% | 41.44% | 42.53% | 42.87% | 44.33% | 44.36% | 44.62% | 44.52% | 44.78% | 45.28% | 44.97% | 45.57% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Aarti Drugs Limited | ₹4,172.86 Cr | ₹466.3 | 21.8 | 2.69 | 12.6% | 0.37 | +6.4% | -7.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Index membership
1 index
Aarti Drugs Share Price Rises 12.25%: Price and Fundamentals
Aarti Drugs Ltd. shares jumped 12.25%, rising to Rs 452.8 from Rs 403.4, with a market cap of Rs 3,465.52 crore. The gain follows a sharp intraday rally, while the company’s P/E of 19.26x and ROE of 13.36% place it below sector valuation averages but above peer median returns.
Pharma sector stocks today, November 17: Aarti Drugs jumps 1.60%, Wockhardt up 1.43%, Zydus Life rises 0.98%
Aarti Drugs rose 1.60% to Rs 509.25, leading gains among pharma stocks on Tuesday, November 17, 2026. The broader market was positive, with the Nifty 50 up 0.27% to 25,359.80, while 11 of 21 pharma shares advanced and 10 fell, indicating mixed sector momentum.